ESTRO 2024 - Abstract Book

S2102

Clinical - Sarcoma, skin cancer, melanoma

ESTRO 2024

Keywords: AYAs, pediatric, rhabdomyosarcoma

References:

1. Bergamaschi, L. et al. Rhabdomyosarcoma in adults: analysis of treatment modalities in a prospective single center series. Med. Oncol. 36, 1 – 8 (2019). 2. Drabbe, C. et al. Embryonal and Alveolar Rhabdomyosarcoma in Adults: Real-Life Data From a Tertiary Sarcoma Centre. Clin. Oncol. 32, e27 – e35 (2020). 3. Dumont, S. N. et al. Management and outcome of 239 adolescent and adult rhabdomyosarcoma patients. Cancer Med. 2, 553 – 563 (2013). 4. Ferrari, A. et al. Adolescents and young adults with rhabdomyosarcoma treated in the European paediatric Soft tissue sarcoma Study Group ( EpSSG ) protocols : a cohort study. Lancet child Adolesc. Heal. 6, 545 – 554 (2022).

1669

Poster Discussion

Patient satisfaction after kilovoltage therapy of basal cell carcinoma: a national prospective study

Oscar Nymann Brændstrup 1 , Pernille Lassen 2 , Anita Birgitte Gothelf 3 , Steen Risgaard De Blanck 3 , Jeppe Friborg 3 , Camilla Kjaer Lonkvist 2 , Anni Linnet Nielsen 2 , Hanne Primdal 4 , Gulalai Hanan 5 , Mamadi Toure 5 , Maria Andersen 6 , Kinga Nowicka-Matus 6 , Rasmus Kjeldsen 6 , Jesper Grau Eriksen 1,4 1 Aarhus University Hospital, Dept. of Experimental Clinical Oncology, Aarhus, Denmark. 2 Herlev and Gentofte Hospital, University of Copenhagen, Dept. of Oncology, Herlev, Denmark. 3 Copenhagen University Hospital, Dept. of Oncology, Copenhagen, Denmark. 4 Aarhus University Hospital, Dept. of Oncology, Aarhus, Denmark. 5 Vejle Hospital, Dept. of Oncology, Vejle, Denmark. 6 Aalborg University Hospital, Dept. of Oncology, Aalborg, Denmark

Purpose/Objective:

Kilovoltage therapy is a qualified treatment option for basal cell carcinoma (BCC), yielding tumor control rates and cosmetic outcome comparable to surgery. Although BCC is the most common cancer in humans, the evidence for kilovoltage therapy is predominantly based on retrospective reports with heterogeneity in tumor dose, fractionation schedule, disease stage and patient-related factors. As of January 1 st 2020, a nationwide prospective collection and registration of patient/tumor characteristics, treatment-related factors (dose and fractionation), and outcome was initiated in Denmark. With the present study we aim to report on patient reported cosmetic outcome six months after kilovoltage therapy for BCC, including investigation of the impact of fractionation and field size.

Material/Methods:

Patients with BCC in the facial region consecutively referred for kilovoltage therapy between January 2020 and December 2022 in five of six Danish centers were identified from the nationwide database and included in the study. Kilovoltage therapy (predominantly 70-100kV) was delivered as either 40.5-45Gy /9-10fx or 51Gy/17fx with a